nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroergotamine—ABCB1—adrenal gland cancer	0.97	1	CbGaD
Dihydroergotamine—Ergotamine—ABCB1—adrenal gland cancer	0.00136	0.509	CrCbGaD
Dihydroergotamine—Bromocriptine—ABCB1—adrenal gland cancer	0.00131	0.491	CrCbGaD
Dihydroergotamine—ADRA2A—GPCR ligand binding—TSHR—adrenal gland cancer	8.91e-05	0.00326	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR ligand binding—GNAS—adrenal gland cancer	8.91e-05	0.00326	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—GNRH1—adrenal gland cancer	8.87e-05	0.00324	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR ligand binding—GNAS—adrenal gland cancer	8.84e-05	0.00323	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—GNRH1—adrenal gland cancer	8.82e-05	0.00323	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—GNRH1—adrenal gland cancer	8.75e-05	0.0032	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—GNRHR—adrenal gland cancer	8.7e-05	0.00318	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR ligand binding—GNAS—adrenal gland cancer	8.66e-05	0.00317	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—TSHR—adrenal gland cancer	8.66e-05	0.00317	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—GNRHR—adrenal gland cancer	8.63e-05	0.00316	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—TSHR—adrenal gland cancer	8.59e-05	0.00314	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—GNRH1—adrenal gland cancer	8.57e-05	0.00314	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—GNRHR—adrenal gland cancer	8.57e-05	0.00313	CbGpPWpGaD
Dihydroergotamine—ADRA2A—G alpha (i) signalling events—GNAS—adrenal gland cancer	8.56e-05	0.00313	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—GNRHR—adrenal gland cancer	8.45e-05	0.00309	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—TSHR—adrenal gland cancer	8.41e-05	0.00308	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR ligand binding—GNAS—adrenal gland cancer	8.13e-05	0.00298	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—SH3KBP1—adrenal gland cancer	8.09e-05	0.00296	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—GNRH1—adrenal gland cancer	8.05e-05	0.00295	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—SH3KBP1—adrenal gland cancer	8.02e-05	0.00294	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—GNRHR—adrenal gland cancer	7.94e-05	0.0029	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—TSHR—adrenal gland cancer	7.9e-05	0.00289	CbGpPWpGaD
Dihydroergotamine—HTR6—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	7.88e-05	0.00288	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—TSHR—adrenal gland cancer	7.86e-05	0.00288	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—SH3KBP1—adrenal gland cancer	7.86e-05	0.00287	CbGpPWpGaD
Dihydroergotamine—HTR1D—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	7.82e-05	0.00286	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—TSHR—adrenal gland cancer	7.8e-05	0.00285	CbGpPWpGaD
Dihydroergotamine—HTR1B—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	7.66e-05	0.0028	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—TSHR—adrenal gland cancer	7.64e-05	0.00279	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—ZNRF3—adrenal gland cancer	7.6e-05	0.00278	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—ZNRF3—adrenal gland cancer	7.54e-05	0.00276	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—ZNRF3—adrenal gland cancer	7.39e-05	0.0027	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—SH3KBP1—adrenal gland cancer	7.38e-05	0.0027	CbGpPWpGaD
Dihydroergotamine—HTR1A—G alpha (i) signalling events—POMC—adrenal gland cancer	7.33e-05	0.00268	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—adrenal gland cancer	7.32e-05	0.00268	CbGpPWpGaD
Dihydroergotamine—HTR1A—SIDS Susceptibility Pathways—CTNNB1—adrenal gland cancer	7.27e-05	0.00266	CbGpPWpGaD
Dihydroergotamine—HTR2B—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	7.19e-05	0.00263	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—GNRH1—adrenal gland cancer	7.19e-05	0.00263	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—TSHR—adrenal gland cancer	7.18e-05	0.00262	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—ZNRF3—adrenal gland cancer	6.94e-05	0.00254	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—SPARC—adrenal gland cancer	6.78e-05	0.00248	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—SDHB—adrenal gland cancer	6.62e-05	0.00242	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR ligand binding—GNAS—adrenal gland cancer	6.6e-05	0.00241	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—GNRH1—adrenal gland cancer	6.53e-05	0.00239	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—GNRHR—adrenal gland cancer	6.44e-05	0.00236	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—TSHR—adrenal gland cancer	6.41e-05	0.00234	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR ligand binding—POMC—adrenal gland cancer	6e-05	0.00219	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—SH3KBP1—adrenal gland cancer	5.98e-05	0.00219	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR ligand binding—POMC—adrenal gland cancer	5.95e-05	0.00218	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Phase 1 - Functionalization of compounds—POMC—adrenal gland cancer	5.93e-05	0.00217	CbGpPWpGaD
Dihydroergotamine—HTR1A—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	5.83e-05	0.00213	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR ligand binding—POMC—adrenal gland cancer	5.83e-05	0.00213	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—TSHR—adrenal gland cancer	5.82e-05	0.00213	CbGpPWpGaD
Dihydroergotamine—ADRA2A—G alpha (i) signalling events—POMC—adrenal gland cancer	5.76e-05	0.00211	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—PRKACA—adrenal gland cancer	5.72e-05	0.00209	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—GNRH1—adrenal gland cancer	5.65e-05	0.00207	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—PRKACA—adrenal gland cancer	5.64e-05	0.00206	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—ZNRF3—adrenal gland cancer	5.63e-05	0.00206	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—PRKACA—adrenal gland cancer	5.6e-05	0.00205	CbGpPWpGaD
Dihydroergotamine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—adrenal gland cancer	5.49e-05	0.00201	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—PRKACA—adrenal gland cancer	5.48e-05	0.00201	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR ligand binding—POMC—adrenal gland cancer	5.48e-05	0.002	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—CDC42—adrenal gland cancer	5.27e-05	0.00193	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—CDC42—adrenal gland cancer	5.23e-05	0.00191	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—GNRH1—adrenal gland cancer	5.21e-05	0.00191	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR ligand binding—GNAS—adrenal gland cancer	5.18e-05	0.0019	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—GNRH1—adrenal gland cancer	5.17e-05	0.00189	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—PRKACA—adrenal gland cancer	5.15e-05	0.00188	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—GNRH1—adrenal gland cancer	5.13e-05	0.00188	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—CDC42—adrenal gland cancer	5.12e-05	0.00187	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—BAD—adrenal gland cancer	5.1e-05	0.00187	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—GNRH1—adrenal gland cancer	5.06e-05	0.00185	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—GNRHR—adrenal gland cancer	5.06e-05	0.00185	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—TSHR—adrenal gland cancer	5.04e-05	0.00184	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—GNAS—adrenal gland cancer	5.04e-05	0.00184	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—GNAS—adrenal gland cancer	5e-05	0.00183	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—GNAS—adrenal gland cancer	4.89e-05	0.00179	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—CDC42—adrenal gland cancer	4.85e-05	0.00177	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—CDC42—adrenal gland cancer	4.81e-05	0.00176	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—CDC42—adrenal gland cancer	4.79e-05	0.00175	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—SPRY2—adrenal gland cancer	4.77e-05	0.00174	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—GNRH1—adrenal gland cancer	4.76e-05	0.00174	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—CDC42—adrenal gland cancer	4.75e-05	0.00174	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—SPRY2—adrenal gland cancer	4.73e-05	0.00173	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—SH3KBP1—adrenal gland cancer	4.7e-05	0.00172	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—IGF2—adrenal gland cancer	4.68e-05	0.00171	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—CDC42—adrenal gland cancer	4.65e-05	0.0017	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TSHR—adrenal gland cancer	4.64e-05	0.0017	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—GNAS—adrenal gland cancer	4.64e-05	0.0017	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—SPRY2—adrenal gland cancer	4.63e-05	0.00169	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TSHR—adrenal gland cancer	4.61e-05	0.00169	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—GNAS—adrenal gland cancer	4.6e-05	0.00168	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	4.58e-05	0.00168	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—SDHB—adrenal gland cancer	4.58e-05	0.00167	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—TSHR—adrenal gland cancer	4.57e-05	0.00167	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—GNAS—adrenal gland cancer	4.57e-05	0.00167	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—GNAS—adrenal gland cancer	4.54e-05	0.00166	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TSHR—adrenal gland cancer	4.51e-05	0.00165	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—GNAS—adrenal gland cancer	4.44e-05	0.00163	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR ligand binding—POMC—adrenal gland cancer	4.44e-05	0.00162	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—ZNRF3—adrenal gland cancer	4.42e-05	0.00162	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—CDC42—adrenal gland cancer	4.37e-05	0.0016	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MEN1—adrenal gland cancer	4.37e-05	0.0016	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—SPRY2—adrenal gland cancer	4.35e-05	0.00159	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MEN1—adrenal gland cancer	4.33e-05	0.00159	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—RRM1—adrenal gland cancer	4.26e-05	0.00156	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—SDHD—adrenal gland cancer	4.26e-05	0.00156	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MEN1—adrenal gland cancer	4.24e-05	0.00155	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TSHR—adrenal gland cancer	4.24e-05	0.00155	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—PRKACA—adrenal gland cancer	4.18e-05	0.00153	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—GNAS—adrenal gland cancer	4.17e-05	0.00153	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MEN1—adrenal gland cancer	3.99e-05	0.00146	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—CDC42—adrenal gland cancer	3.9e-05	0.00143	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—GNRH1—adrenal gland cancer	3.86e-05	0.00141	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—adrenal gland cancer	3.75e-05	0.00137	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—GNAS—adrenal gland cancer	3.73e-05	0.00136	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—CDC42—adrenal gland cancer	3.54e-05	0.0013	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—SPRY2—adrenal gland cancer	3.53e-05	0.00129	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR ligand binding—POMC—adrenal gland cancer	3.49e-05	0.00128	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TSHR—adrenal gland cancer	3.44e-05	0.00126	CbGpPWpGaD
Dihydroergotamine—ABCB1—Transmembrane transport of small molecules—PRKACA—adrenal gland cancer	3.42e-05	0.00125	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—POMC—adrenal gland cancer	3.39e-05	0.00124	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—GNAS—adrenal gland cancer	3.38e-05	0.00124	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—POMC—adrenal gland cancer	3.36e-05	0.00123	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—adrenal gland cancer	3.36e-05	0.00123	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—PRKACA—adrenal gland cancer	3.33e-05	0.00122	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—PRKACA—adrenal gland cancer	3.31e-05	0.00121	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—POMC—adrenal gland cancer	3.29e-05	0.00121	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—PRKACA—adrenal gland cancer	3.28e-05	0.0012	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—PRKACA—adrenal gland cancer	3.24e-05	0.00118	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MEN1—adrenal gland cancer	3.23e-05	0.00118	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—MED12—adrenal gland cancer	3.18e-05	0.00116	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Biological oxidations—POMC—adrenal gland cancer	3.15e-05	0.00115	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—POMC—adrenal gland cancer	3.09e-05	0.00113	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—POMC—adrenal gland cancer	3.08e-05	0.00113	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—CDC42—adrenal gland cancer	3.07e-05	0.00112	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—POMC—adrenal gland cancer	3.06e-05	0.00112	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—PRKACA—adrenal gland cancer	3.04e-05	0.00111	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—GNRH1—adrenal gland cancer	3.03e-05	0.00111	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—POMC—adrenal gland cancer	2.99e-05	0.00109	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—RRM1—adrenal gland cancer	2.95e-05	0.00108	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—SDHD—adrenal gland cancer	2.95e-05	0.00108	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—GNAS—adrenal gland cancer	2.93e-05	0.00107	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CDC42—adrenal gland cancer	2.83e-05	0.00103	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—SDHB—adrenal gland cancer	2.82e-05	0.00103	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—POMC—adrenal gland cancer	2.81e-05	0.00103	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CDC42—adrenal gland cancer	2.81e-05	0.00103	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—CDC42—adrenal gland cancer	2.78e-05	0.00102	CbGpPWpGaD
Dihydroergotamine—ABCB1—Transmembrane transport of small molecules—GNAS—adrenal gland cancer	2.77e-05	0.00102	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—SPRY2—adrenal gland cancer	2.77e-05	0.00101	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CDC42—adrenal gland cancer	2.75e-05	0.001	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IGF2—adrenal gland cancer	2.72e-05	0.000997	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IGF2—adrenal gland cancer	2.7e-05	0.000989	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TSHR—adrenal gland cancer	2.7e-05	0.000988	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—GNAS—adrenal gland cancer	2.7e-05	0.000988	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—GNAS—adrenal gland cancer	2.68e-05	0.000981	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—adrenal gland cancer	2.66e-05	0.000973	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—GNAS—adrenal gland cancer	2.66e-05	0.000973	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IGF2—adrenal gland cancer	2.65e-05	0.000969	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—IGF1R—adrenal gland cancer	2.63e-05	0.000964	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—GNAS—adrenal gland cancer	2.62e-05	0.00096	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—IGF1R—adrenal gland cancer	2.61e-05	0.000956	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CDC42—adrenal gland cancer	2.58e-05	0.000944	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—IGF1R—adrenal gland cancer	2.56e-05	0.000936	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MEN1—adrenal gland cancer	2.54e-05	0.000929	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—POMC—adrenal gland cancer	2.51e-05	0.000918	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IGF2—adrenal gland cancer	2.49e-05	0.00091	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—PRKACA—adrenal gland cancer	2.47e-05	0.000902	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—GNAS—adrenal gland cancer	2.47e-05	0.000902	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—IGF1R—adrenal gland cancer	2.4e-05	0.00088	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PRKACA—adrenal gland cancer	2.32e-05	0.000848	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—POMC—adrenal gland cancer	2.28e-05	0.000834	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TERT—adrenal gland cancer	2.27e-05	0.00083	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TERT—adrenal gland cancer	2.25e-05	0.000823	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—adrenal gland cancer	2.23e-05	0.000817	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TERT—adrenal gland cancer	2.2e-05	0.000806	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—MED12—adrenal gland cancer	2.2e-05	0.000804	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CDC42—adrenal gland cancer	2.09e-05	0.000766	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TERT—adrenal gland cancer	2.07e-05	0.000757	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IGF2—adrenal gland cancer	2.02e-05	0.000738	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—GNAS—adrenal gland cancer	2e-05	0.000731	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—BAD—adrenal gland cancer	1.97e-05	0.000722	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—POMC—adrenal gland cancer	1.97e-05	0.000722	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—BAD—adrenal gland cancer	1.96e-05	0.000716	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—IGF1R—adrenal gland cancer	1.95e-05	0.000713	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—PRKACA—adrenal gland cancer	1.94e-05	0.000709	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—BAD—adrenal gland cancer	1.92e-05	0.000701	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—GNAS—adrenal gland cancer	1.88e-05	0.000688	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—ABCB1—adrenal gland cancer	1.84e-05	0.000675	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—POMC—adrenal gland cancer	1.82e-05	0.000665	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—RRM1—adrenal gland cancer	1.82e-05	0.000664	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—SDHD—adrenal gland cancer	1.82e-05	0.000664	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—POMC—adrenal gland cancer	1.8e-05	0.00066	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—BAD—adrenal gland cancer	1.8e-05	0.000659	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—BRAF—adrenal gland cancer	1.8e-05	0.000657	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—POMC—adrenal gland cancer	1.79e-05	0.000655	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—BRAF—adrenal gland cancer	1.78e-05	0.000652	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—POMC—adrenal gland cancer	1.77e-05	0.000647	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—BRAF—adrenal gland cancer	1.75e-05	0.000638	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—EGFR—adrenal gland cancer	1.74e-05	0.000637	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—EGFR—adrenal gland cancer	1.73e-05	0.000632	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—EGFR—adrenal gland cancer	1.69e-05	0.000619	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TERT—adrenal gland cancer	1.68e-05	0.000614	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—POMC—adrenal gland cancer	1.66e-05	0.000607	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CDC42—adrenal gland cancer	1.64e-05	0.000602	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—BRAF—adrenal gland cancer	1.64e-05	0.0006	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PRKACA—adrenal gland cancer	1.6e-05	0.000587	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—EGFR—adrenal gland cancer	1.59e-05	0.000581	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IGF2—adrenal gland cancer	1.59e-05	0.00058	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—GNAS—adrenal gland cancer	1.57e-05	0.000575	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—IGF1R—adrenal gland cancer	1.53e-05	0.000561	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—TP53—adrenal gland cancer	1.48e-05	0.000542	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—BAD—adrenal gland cancer	1.46e-05	0.000534	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—MED12—adrenal gland cancer	1.35e-05	0.000495	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—POMC—adrenal gland cancer	1.35e-05	0.000493	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—BRAF—adrenal gland cancer	1.33e-05	0.000486	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TERT—adrenal gland cancer	1.32e-05	0.000483	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—GNAS—adrenal gland cancer	1.3e-05	0.000475	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CTNNB1—adrenal gland cancer	1.3e-05	0.000475	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—EGFR—adrenal gland cancer	1.29e-05	0.000471	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CTNNB1—adrenal gland cancer	1.29e-05	0.000471	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—POMC—adrenal gland cancer	1.27e-05	0.000463	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CTNNB1—adrenal gland cancer	1.26e-05	0.000461	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CTNNB1—adrenal gland cancer	1.18e-05	0.000433	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—BAD—adrenal gland cancer	1.15e-05	0.00042	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—POMC—adrenal gland cancer	1.06e-05	0.000387	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—BRAF—adrenal gland cancer	1.04e-05	0.000382	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—EGFR—adrenal gland cancer	1.03e-05	0.000376	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—EGFR—adrenal gland cancer	1.02e-05	0.000373	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—EGFR—adrenal gland cancer	1.01e-05	0.00037	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—PTGS2—adrenal gland cancer	1.01e-05	0.000369	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—EGFR—adrenal gland cancer	9.99e-06	0.000366	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PRKACA—adrenal gland cancer	9.88e-06	0.000361	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CTNNB1—adrenal gland cancer	9.61e-06	0.000351	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—EGFR—adrenal gland cancer	9.39e-06	0.000343	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—POMC—adrenal gland cancer	8.75e-06	0.00032	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TP53—adrenal gland cancer	8.63e-06	0.000316	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TP53—adrenal gland cancer	8.57e-06	0.000313	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TP53—adrenal gland cancer	8.39e-06	0.000307	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—GNAS—adrenal gland cancer	8.01e-06	0.000293	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TP53—adrenal gland cancer	7.88e-06	0.000288	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—ABCB1—adrenal gland cancer	7.86e-06	0.000287	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—EGFR—adrenal gland cancer	7.61e-06	0.000278	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CTNNB1—adrenal gland cancer	7.55e-06	0.000276	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—PTGS2—adrenal gland cancer	6.98e-06	0.000255	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TP53—adrenal gland cancer	6.39e-06	0.000234	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—EGFR—adrenal gland cancer	5.98e-06	0.000219	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—POMC—adrenal gland cancer	5.39e-06	0.000197	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TP53—adrenal gland cancer	5.02e-06	0.000184	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—PTGS2—adrenal gland cancer	4.3e-06	0.000157	CbGpPWpGaD
